A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the hypothesis that treatment with study medication
(omarigliptin; MK-3102) provides greater reduction in A1C Hemoglobin (a marker of diabetic
severity) compared with placebo, after 12 weeks of treatment. The study will evaluate 5
different doses of omarigliptin to identify which dose is the most effective in the treatment
of type 2 diabetes.